Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
ConditionAML, Adult
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorETH Zurich
About this trial
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
Eligibility criteria
Qualifiers
Patient with refractory or relapsed AML according to ELN2022 criteria.
Age 18-70 years.
Considered to be eligible for intensive chemotherapy.
Written informed consent.
Disqualifiers
Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic variant fusion genes/chromosome translocations.
Blast crisis after chronic myeloid leukemia (CML).
Considered not eligible for intensive chemotherapy.
Condition of the patient does not allow to wait for PCY results (patient requires immediate treatment).
Trial design
Treatments tested in this trial
- Pharmacoscopy
- Clinical standard-of-care (physician's choice)
Treatment groups
88 Participants
are divided into 2 treatment groupsSponsors and collaborators
ETH Zurich
Lead sponsor
University of Zurich
Collaborator
Insel Gruppe AG, University Hospital Bern
Collaborator
Source ClinicalTrials.gov